Humoral immune responses against the immature laminin receptor protein show prognostic significance in patients with chronic lymphocytic leukemia

The Journal of Immunology : Official Journal of the American Association of Immunologists
Birte FriedrichsMatthias Zeis

Abstract

Chronic lymphocytic leukemia (CLL) is characterized by a highly variable clinical course. The role of an autologous tumor-specific immune control contributing to the variable length of survival in CLL is poorly understood. We investigated whether humoral immunity specific for the CLL-associated Ag oncofetal Ag/immature laminin receptor (OFA/iLR) has a prognostic value in CLL. Among sera of 67 untreated patients with CLL, 23 (34.3%) had detectable OFA/iLR Abs that were reactive for at least one specific OFA/iLR epitope. Patients with humoral responses compared with patients with nonreactive sera had a longer progression-free survival (p = 0.029). IgG subclass analyses showed a predominant IgG1 and IgG3 response. OFA/iLR Abs were capable of recognizing and selectively killing OFA/iLR-expressing CLL cells in complement-mediated and Ab-dependent cellular cytotoxicity assays. In the analysis of 11 CLL patients after allogeneic hematopoietic stem cell transplantation, 8 showed high values for OFA/iLR Abs that specifically recognized the extracellular domain of the protein, suggesting a potential role of anti-OFA/iLR-directed immune responses to the graft-vs-leukemia effect in CLL. Our data suggest that spontaneous tumor-specific humo...Continue Reading

References

May 23, 1998·The Journal of Experimental Medicine·E StockertL J Old
Sep 24, 1998·Immunology Today·J H CogginJ W Rohrer
Feb 7, 2001·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·S M AnsellT E Witzig
Jan 17, 2003·The New England Journal of Medicine·Lin ZhangGeorge Coukos
May 2, 2003·The New England Journal of Medicine·Marta CrespoEmili Montserrat
Jul 11, 2003·Proceedings of the National Academy of Sciences of the United States of America·Sacha GnjaticLloyd J Old
Feb 14, 2004·Blood·Freda K Stevenson, Federico Caligaris-Cappio
Nov 19, 2004·The New England Journal of Medicine·Sandeep S DaveLouis M Staudt
Oct 4, 2005·Journal of Biomedical Informatics·Thomas A LaskoLucila Ohno-Machado
Jan 5, 2006·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Vivian GoodellMary L Disis
Apr 18, 2006·Seminars in Oncology·Till SeilerStephan Stilgenbauer

❮ Previous
Next ❯

Citations

Jan 30, 2015·Biological Reviews of the Cambridge Philosophical Society·Vincent DiGiacomo, Daniel Meruelo
Jun 2, 2017·Journal of Computational Biology : a Journal of Computational Molecular Cell Biology·Yu ZhengQiusheng Chen
Jan 15, 2011·Clinical & Developmental Immunology·Sebastian KoboldDjordje Atanackovic
Feb 26, 2011·Clinical & Developmental Immunology·Zheng-Cai JiaYu-Zhang Wu
Aug 1, 2014·Cancer Immunology, Immunotherapy : CII·Tim LuetkensDjordje Atanackovic

❮ Previous
Next ❯

Related Concepts

Related Feeds

Acute Myeloid Leukemia

Acute myeloid leukemia (AML) is a clinically and genetically heterogeneous disease with approximately 20,000 cases per year in the United States. AML also accounts for 15-20% of all childhood acute leukemias, while it is responsible for more than half of the leukemic deaths in these patients. Here is the latest research on this disease.

Adrenocortical Carcinoma

Adrenocortical carcinoma (ACC) is a rare malignancy of the adrenal cortex, associated with a generally dismal prognosis owing to its aggressive behavior. Here are the latest discoveries pertaining to this disease.

Allogenic & Autologous Therapies

Allogenic therapies are generated in large batches from unrelated donor tissues such as bone marrow. In contrast, autologous therapies are manufactures as a single lot from the patient being treated. Here is the latest research on allogenic and autologous therapies.

Antibody Specificity

Antibodies produced by B cells are highly specific for antigen as a result of random gene recombination and somatic hypermutation and affinity maturation. As the main effector of the humoral immune system, antibodies can neutralize foreign cells. Find the latest research on antibody specificity here.

Blood And Marrow Transplantation

The use of hematopoietic stem cell transplantation or blood and marrow transplantation (bmt) is on the increase worldwide. BMT is used to replace damaged or destroyed bone marrow with healthy bone marrow stem cells. Here is the latest research on bone and marrow transplantation.

B-Cell Leukemia (Keystone)

B-cell leukemia includes various types of lymphoid leukemia that affect B cells. Here is the latest research on B-cell leukemia.

Antibody-Dependent Cell Cytotoxicity

Antibody-dependent cellular toxicity refers to the lysis of a target cell by a non-sensitized effector cell of the immune system as a result of antibodies binding to the target cell membrane and engaging the Fc receptors on the immune effector cells. Find the latest research on antibody-dependent cellular toxicity here.

AML: Role of LSD1 by CRISPR (Keystone)

Find the latest rersearrch on the ability of CRISPR-Cas9 mutagenesis to profile the interactions between lysine-specific histone demethylase 1 (LSD1) and chemical inhibitors in the context of acute myeloid leukemia (AML) here.

Cancer Biology: Molecular Imaging

Molecular imaging enables noninvasive imaging of key molecules that are crucial to tumor biology. Discover the latest research in molecular imaging in cancer biology in this feed.